Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cance... ( SEATTLE Aug. 17 /- Dendreon Corpo...)

HOME >> MEDICINE >> TECHNOLOGY

Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

Date:8/19/2007

SEATTLE, Aug. 17 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced publication of results from a Phase 1 study of NEUVENGE, an investigational active cellular immunotherapy, in the August 20 issue of the Journal of Clinical Oncology. The article highlights the safety profile, immune response and clinical activity of NEUVENGE in women with HER2/neu-positive breast cancer who have failed standard therapy.

"In addition to demonstrating that NEUVENGE was safe and well tolerated, the T-cell responses seen in these patients and the prolonged disease stabilization in the absence of other anti-cancer therapies in many patients is promising," said John W. Park, M.D., associate clinical professor of medicine and neurosurgery at the University of California, San Francisco and lead author of the publication. "These observations are encouraging and are suggestive of the clinical benefit of NEUVENGE, particularly in light of the aggressive cancer seen in these patients who had progressed while on standard therapy. The findings warrant additional studies of NEUVENGE for the many women with advanced breast cancer who have exhausted many of their treatment options."

Study Design

The Phase 1 study (D2000-2) was conducted to evaluate the safety and immunologic activity of NEUVENGE in patients with HER2-overexpressing metastatic breast cancer who had failed standard therapy, including prior treatment with chemotherapy and trastuzumab. All patients had experienced disease progression while on standard therapy. There were 19 patients enrolled in the study with 18 patients receiving treatment with NEUVENGE. Patients underwent three infusions of NEUVENGE at Weeks 0, 2, and 4 following randomizati
'/>"/>

SOURCE Dendreon Corporation

3

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study

Post Your Comments:

(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...

(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012 Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...

(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...

Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2 Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3 Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2 Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3 GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4 ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1 ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3 MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4

[0] Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting [0] Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream [0] Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.

... blood ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. 17 ... reveals Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark of the ... which leads to an increase in blood flow and oxygen supply,to ...

... Joint Venture Between Bristol-Myers Squibb, Company ... in HIV Treatment -, PRINCETON, N.J. and ... Company (NYSE: BMY ) and Gilead Sciences, ... Canada has approved ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 mg/tenofovir ...

New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...

(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...

(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...

(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...

(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...

Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2 Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2 Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3 Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4 Health News:Cleft lip/palate cause much more than cosmetic problems 2

[0] Landmark textbook on health care and the US legal system released [0] Aggregating instead of stabilizing: New insights into the mechanisms of heart disease [0] Viral infections in infancy are not associated with wheezing symptoms in later childhood [0] Mayo Clinic urologists present findings at American Urological Association Annual Meeting [0] Cleft lip/palate cause much more than cosmetic problems

... Inc. (NYSE: CSV ) today announced results for the first quarter ended March 31, 2009. Highlights from continuing operations for ... in millions, except per share amounts) , , ... Q1, ... Change, ...

... Inc.,s parent company, Team Finance LLC (the "Company"), today announced ... less provision for uncollectibles ("revenue less provision") in the first ... million in the first quarter of 2008. Same contract ... million from $305.5 million in the same period a year ...

... of these meds with their doctor, cardiac group says ... takes the clot-preventing drug Plavix after receiving a stent ... medications called proton pump inhibitors (PPIs), if possible, a ... blockbuster acid reflux medications such as Nexium, Prevacid and ...

... Contributions emphasize need for improved mental health services ... The Regence Foundation announced today it awarded $390,000 ... Idaho, Oregon, Utah and Washington. Five of the ... organizations nominated by Regence employees as part of ...

... age of those hospitalized in U.S. is 15, CDC says ... majority of U.S. cases continue to be mild, those who ... atypically young, health officials said Wednesday. , In fact, the ... which is younger than occurs in regular seasonal flu, U.S. ...

... The following was released today by Americans for ... National Institute for Occupational Safety and Health (NIOSH) ... dangerous levels of secondhand smoke at work. NIOSH recommends ... casinos is safe for workers to breathe. In 2005, ...

Carriage Services Announces First Quarter 2009 Results Team Finance LLC Announces First Quarter 2009 Results Plavix, Heartburn Drugs May Be Risky Combination Regence Foundation Grants $390,000 to Improve Health Care Safety Net Younger Age of Severe Swine Flu Cases Worries Experts No Safe Bets for Casino Workers: NIOSH Study Shows Casino Workers Face Toxic Conditions

Slick® Disposable Endotracheal Stylet, Nylon-coated wire, Malleable core, Sureloc Stop helps maintain desired length for patient safety. Handle forming capability for better grip. Sterile. Single...

Stylet - Infant Stainless Steel, Flexible, Non-Sterile, Latex Free, With stop, Suitable for tubes 2.0 mm I.D. or larger....

... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...

All endotracheal accessories are designed to ensure your technique. The Blue Line® intubation stylets feature a satin-smooth coating and are available in three sizes....

Medicine Products:

Slick® Disposable Endotracheal Stylet 6 Fr Endotracheal Tube Stylet - Infant Lighted Pediatric Stylet - Sterile Blue Line® Intubation Stylet 5.0 mm 7.0 mm

Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cance...( SEATTLE Aug. 17 /- Dendreon Corpo...),Health